Familiality and SNP heritability of age at onset and episodicity in major depressive disorder

P. Ferentinos1,2*, A. Koukounari3, R. Power1, M. Rivera1,4, R. Uher3,5, N. Craddock6, M. J. Owen6, A. Korszun7, L. Jones8, I. Jones6, M. Gill9, P. McGuffin1 and C. M. Lewis1,2

1 MRC Social Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, UK; 2supported Department of Psychiatry, Attikon General Hospital, University of Athens, Athens, Greece; 3Department of Biostatistics, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, UK; 4Centro de Investigación Biomédica en Red de Salud Mental CIBERSAM, University of Granada, Spain; 5Dalhousie University Department of Psychiatry, Halifax, Nova Scotia, Canada; 6MRC Centre for Neuropsychiatric Genetics and Genomics, Neuroscience and Mental Health Research Institute, Cardiff University, Cardiff, UK; 7Bars and The London Medical School, Queen Mary University of London, London, UK; 8Department of Psychiatry, Trinity Centre for Health Science, Dublin, Ireland; 9Department of Psychology, Washington University, St. Louis, Missouri, USA; 10Max Planck Institute of Psychiatry, Munich, Germany; 11Department of Psychiatry, University of Bonn & German Center of Neurodegenerative Diseases (DZNE), Bonn, Germany; 12Centre for Psychiatric Research, Aarhus University Hospital, Risskov, Denmark; 13Division of Genetic Epidemiology in Psychiatry, Central Institute of Mental Health, Mannheim, Germany; 14MRC University Hospital Center and University of Lausanne, Lausanne, Switzerland; 15Division of Psychiatry and Medical Genetics, University of Alberta, Edmonton, Alberta, Canada; 16Department of Psychiatry, Free University of Brussels, Brussels, Belgium; 17Centre Européen de Psychologie Médicale PSY-PLURIEL, Bruxelles, Belgium; 18Department of Genetics in Psychiatry, Poznan University of Medical Sciences, Poznan, Poland; 19Department of Psychiatry, University of Zagreb, Zagreb, Croatia; 20NIHR Biomedical Research Centre for Mental Health, South London and Maudsley NHS Foundation Trust and Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, UK; 21Division of Genetics and Molecular Medicine, King’s College London, London, UK.

Background. Strategies to dissect phenotypic and genetic heterogeneity of major depressive disorder (MDD) have mainly relied on subphenotypes, such as age at onset (AAO) and recurrence/episodicity. Yet, evidence on whether these subphenotypes are familial or heritable is scarce. The aims of this study are to investigate the familiality of AAO and episode frequency in MDD and to assess the proportion of their variance explained by common single nucleotide polymorphisms (SNP heritability).

Method. For investigating familiality, we used 691 families with 2–5 full siblings with recurrent MDD from the DeNt study. We fitted (square root) AAO and episode count in a linear and a negative binomial mixed model, respectively, with family as random effect and adjusting for sex, age and center. The strength of familiality was assessed with intraclass correlation coefficients (ICC). For estimating SNP heritabilities, we used 3468 unrelated MDD cases from the RADIANT and GSK Munich studies. After similarly adjusting for covariates, derived residuals were used with the GREML method in GCTA (genome-wide complex trait analysis) software.

Results. Significant familial clustering was found for both AAO (ICC = 0.28) and episodicity (ICC = 0.07). We calculated from respective ICC estimates the maximal additive heritability of AAO (0.56) and episodicity (0.15). SNP heritability of AAO was 0.17 (p = 0.04); analysis was underpowered for calculating SNP heritability of episodicity.

Conclusions. AAO and episodicity aggregate in families to a moderate and small degree, respectively. AAO is under stronger additive genetic control than episodicity. Larger samples are needed to calculate the SNP heritability of episodicity. The described statistical framework could be useful in future analyses.

Received 25 October 2014; Revised 11 January 2015; Accepted 22 January 2015; First published online 20 February 2015

Key words: Age at onset, episodicity, familiality, GCTA, heritability, major depression.

Introduction

Despite extensive research in the field, the genetic architecture of major depressive disorder (MDD) remains highly elusive. Eight genome-wide association studies (GWAS) of MDD have been published (Sullivan et al. 2009; Lewis et al. 2010; Muglia et al. 2010; Rietschel et al. 2010; Kohli et al. 2011; Shi et al.)
phenotypic variance explained by additive genetic effectability of quantitative traits, i.e. the percentage of evidence on whether these subphenotypes are pairs with MDD (Kendler et al. 2004; McGuffin et al. 2005; Breen et al. 2011), which comprises cases of recurrent depression fulfilling DSM-IV and/or ICD-10 criteria of at least moderate severity ascertained from three UK clinical sites (London, Cardiff, Birmingham), four other European sites (Aarhus, Bonn, Dublin, Lausanne) and a site in St Louis, USA. One familial cluster of affected full siblings was identified in each family; in extended families, we used only the sibship including the proband or the sibship with complete data on AAO and episode frequency. A total of 1498 subjects from 691 families with 2–5 affected full siblings were extracted for statistical analysis (Table 1).

For the assessment of the SNP heritability of AAO, we used 3468 genotyped, unrelated MDD cases with complete data on age and AAO; 2695 cases were obtained from the RADIANT study, i.e. from the Depression Case-Control (DeCC) (N = 1023), DeNt (N = 843), GSK Case-Control (N = 140) and GENDEP (N = 689) studies, while 773 cases were obtained from the GSK Munich study. The DeCC study includes cases of recurrent depression of at least moderate severity ascertained from three UK sites (London, Cardiff, Birmingham) (Cohen-Woods et al. 2009). One proband from each DeNt family was genotyped and also included in the RADIANT study. The GSK Case-Control study includes cases of recurrent depression collected in Bonn and Lausanne in collaboration with GSK, using exactly the same protocol as the DeNt study. Cases from GENDEP (Uher et al. 2009), a pharmacogenetic study, were ascertained from various sites across Europe (London, Brussels, Mannheim, Bonn, Brescia, Aarhus, Ljubljana, Poznan, Zagreb); while recurrence was not a requirement, 59.5% of GENDEP cases suffered from recurrent MDD. The GSK Munich sample includes cases of recurrent depression of at least moderate severity recruited for a case-control study in the Munich area in collaboration with GSK (Tozzi et al. 2008; Muglia et al. 2010). To calculate the SNP heritability of episodicity, we extracted a subset of 2368 cases with recurrent MDD from the total sample with complete data on episode count (as well as on age and AAO), i.e. 994 DeCC, 833 DeNt, 139 GSK Case-Control and 402 GSK Munich cases.

In the RADIANT studies, only adults of European ancestry were recruited. Subjects were excluded if
there was a history or family history (in first- or second-degree relatives) of schizophrenia, schizoaffective disorder or bipolar disorder, if they had experienced mood-incongruent psychotic symptoms, or if mood symptoms were solely related to alcohol or substance misuse or only secondary to medical illness or medication. Inclusion/exclusion criteria in the GSK Munich study were identical to those used in the DeCC and DeNT studies, except that subjects with a family history of bipolar disorder were not excluded. Therefore, we removed the latter from the analyses.

All subjects were interviewed with the Schedules for Clinical Assessment in Neuropsychiatry (SCAN; Wing et al. 1990), focusing on their worst and second-worst episodes of depression. AAO was recorded in SCAN items 1.016, 1.046–1.048 and 6.025; episode count was recorded in SCAN items 1.053 and 6.030. Family history of MDD in first-degree relatives was also extracted from SCAN item 1.045. All study participants provided written informed consent and approval was obtained from local ethics committees.

Whole-genome genotyping in the RADIANT sample was performed using the Illumina HumanHap610-Quad BeadChip. Genotyping in the GSK Munich sample was performed on the Illumina Human-Hap550K platform. Stringent quality control procedures were applied to individual and SNP data in both studies leaving a total of 471,581 and 511,503 SNPs, respectively, finally eligible for analysis (for full details see Lewis et al. 2010; Muglia et al. 2010). The two samples were then merged using PLINK v. 1.07 (Purcell et al. 2007) and taking into account flipped strands issues; the merged sample, including 427,946 SNPs shared by the original samples, was finally used with GCTA software.

Ethical standards

The authors assert that all procedures contributing to this work comply with the ethical standards of the relevant national and institutional committees on human experimentation and with the Helsinki Declaration of 1975, as revised in 2008.

Method

Statistical modeling

Descriptive statistics were used to investigate the distributions of all variables in the DeNT families and genotyped case sets. AAO was analyzed as a continuous variable in linear mixed models; however, as it had a positively skewed distribution, it was first transformed to square root AAO (sqrtAAO) to approach normality. Lifetime number of depressive episodes was a count variable; therefore, we considered Poisson and negative binomial (NB) models as most suitable in subsequent analyses. Episode frequency was defined as the rate of the lifetime number of depressive episodes over the total duration of MDD (=age – age at onset). As its distribution was also highly skewed, a natural logarithm transformation (lnepisfreq) was used for this dependent variable in fitted linear models.

Investigation of familial effects

To investigate the familiality of AAO in the DeNT siblings sample, we initially fitted a three-level linear mixed model (LMM) with sqrtAAO as the dependent variable, sex as fixed effect covariate and center and family as random effects (subjects nested within families; families nested within centers). Familiality of sqrtAAO was documented if the variance of the random effect of family was significantly greater than zero. The strength of the familial effect was measured by calculating the family-level residual intraclass correlation coefficient (ICC) and its confidence interval (CI) (Wynants et al. 2013); the residual ICC represents the proportion of the residual variance of sqrtAAO (after taking into account the effect of fixed covariates – in this case sex) accounted for by family membership. As it has been suggested that AAO can be considered a censored variable and siblings correlated in chronological age will also tend to be correlated in AAO (Schulze et al. 2006), we also fitted a model additionally including age as a fixed effects covariate and calculated the significance of the family random effect as well as the ICC. Analyses were implemented with the Stata v. 13 (StataCorp, 2013) mixed command.

To investigate the familiality of episodicity in the DeNT siblings sample, we employed two methods. In the first method, we fitted a two-level NB generalized linear mixed model (GLMM) with episode count as the dependent variable, sex, age and center as fixed effects covariates, (ln)MDD duration as offset variable (this reflects the time over which the count response is generated) and family as random effect (subjects nested within families; families nested within centers). Analysis was performed with the Stata v. 13 mnebreg command, with adaptive Gauss–Hermite quadrature as integration

<table>
<thead>
<tr>
<th>Number of affected siblings per family</th>
<th>Number of families</th>
<th>Number of affected individuals (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2</td>
<td>600</td>
<td>1200 (80.1)</td>
</tr>
<tr>
<td>3</td>
<td>73</td>
<td>219 (14.6)</td>
</tr>
<tr>
<td>4</td>
<td>11</td>
<td>44 (2.9)</td>
</tr>
<tr>
<td>5</td>
<td>7</td>
<td>35 (2.3)</td>
</tr>
<tr>
<td>Total</td>
<td>691</td>
<td>1498 (100.0)</td>
</tr>
</tbody>
</table>
method (seven integrations points) (Bolker et al. 2009). Familiality of episodicity was similarly assessed by testing whether the variance of the family random effect was significantly greater than zero. The family-level ICC for episodicity and its CI, i.e. the proportion of the variance of episode frequency explained by family membership after taking into account the effect of center, were finally calculated in a ‘reduced’ version of our model, i.e. one without any subject-level covariates (sex, age), on the basis of recent work formulating an ICC in GLMMs for overdispersed count data (see Supplementary Method) (Carrasco, 2010). We also used a second method to investigate the familiality of episodicity as it was previously used to investigate the familial variation of episode frequency in bipolar disorder (Fisfalen et al. 2005); we fitted a three-level LMM with Inepisfreq as the dependent variable, sex and age as fixed effects covariates, and center and family as random effects (subjects nested within families; families nested within centers). Familiality of Inepisfreq was similarly investigated. A family-level residual ICC and its CI were finally calculated.

**Inference of narrow-sense heritability from familiality**

Observed phenotypic covariance between relatives (familiality) can be partitioned to causal genetic and environmental covariance components; for full siblings, phenotypic covariance is the sum of half their additive genetic variance plus a quarter of the dominance variance plus the shared environment variance (the contribution of epistatic interactions is ignored) (COVFS = 1/2V_A + 1/4V_D + V_C) and their phenotypic correlation is the ratio of their phenotypic covariance by the phenotypic variance (ICC = COVFS/V_P) (Falconer & Mackay, 1996; Tenesa & Haley, 2013). Therefore, twice the full-siblings correlation (2 × ICC) is a good estimate of narrow-sense heritability (V_A/V_P) only when dominance and shared environment contributions are assumed negligible and can hence provide an upper bound estimate of heritability (‘maximal heritability’).

**Assessment of SNP heritabilities**

To investigate the SNP heritability of AAO in genotyped cases, we employed two methods to obtain an adjusted episode frequency variable. In the first method, we fitted a NB GLMM (Stata v. 13 `menbreg` command) with episode count as the dependent variable, sex, age and study as fixed-effects covariates, center as random effect, (ln)MDD duration as offset variable, and saved episode frequency deviance residuals. As their distribution was slightly skewed, we rank-normalized them using Blom’s formula (Blom, 1958). The rank-normalized adjusted episode frequency residuals were then used to calculate the SNP heritability of episode frequency with GCTA software, using the same specifications as above. In the second method, we fitted a LMM with Inepisfreq as the dependent variable, sex and age as fixed-effects covariates, and center as random effect. We then saved the residuals, rank-normalized them using Blom’s formula, and finally used them with GCTA software as previously described.

We finally estimated the SNP heritabilities of AAO and episodicity that could be detected with a power of 80% (Visscher et al. 2014).

**Results**

Demographic and clinical characteristics of DeNt siblings and genotyped cases (RADIANT and GSK Munich samples and their merge) are shown in Table 2 and Supplementary Table S1. Frequency distributions (histograms) of age, AAO, episode count and episode frequency in genotyped cases (Fig. 1, Supplementary Fig. S2) and in DeNT siblings (Supplementary Fig. S1) were plotted.

**Familiality of AAO and episode frequency**

In the LMM for sqrtAAO in the DeNt sample (N = 1403), the variance of the family random effect was significantly greater than zero; the family-level residual ICC was 0.278 (95% CI 0.185–0.395) (Table 3, Supplementary Table S2a). When we additionally included age as a fixed-effects covariate in our model, we obtained a lower but still significant family-level residual ICC of 0.229 (95% CI 0.140–0.354) (Table 3, Supplementary Table S2b).

Our NB GLMM for episodicity in the DeNt sample (N = 878) fitted the observed data better than a corresponding Poisson model (Supplementary Table S3). The variance of the family random effect was significantly greater than zero in both the ‘full’ and the ‘reduced’ model (Table 3, Supplementary Table S3). The family-level ICC for episodicity and its CI were calculated on our ‘reduced’ model (online Supplementary Table S3b). We recorded the overdispersion (alpha) parameter and the variance of the
family random effect; we also calculated center variance and episode frequency marginal expectation over families. The family-level ICC for episodicity was finally estimated with the Stata v. 13 *nlcom* command using all aforementioned parameter estimates on the basis of Carrasco’s formulae (full details in Supplementary Method); ICC = 0.074, s.e. = 0.012 (95% CI 0.051–0.096).

In the LMM for lnepisfreq in the DeNt sample, the variance of the family random effect was significantly greater than zero; the family-level residual ICC was 0.167 (95% CI 0.089–0.292) (Table 3, Supplementary Table S4).

**Calculation of ‘maximal heritability’ from familiality (ICC estimates)**

Assuming dominance and shared environment variance components are negligible, narrow-sense heritability reaches its upper limit (‘maximal heritability’), which is twice the ICC estimate. Maximal heritability estimates obtained are 0.46 and 0.56 for AAO

---

**Table 2. Demographic and clinical characteristics of DeNT siblings and genotyped cases (merged RADIANT and GSK Munich samples)**

<table>
<thead>
<tr>
<th></th>
<th>DeNT siblings (N = 1498)</th>
<th>Genotyped cases (N = 3468)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex (females)</td>
<td>73.4% (N = 1498)</td>
<td>69.8% (N = 3468)</td>
</tr>
<tr>
<td>Age (yr)</td>
<td>44.8 ± 11.9 (18–80) (N = 1498)</td>
<td>46.2 ± 12.7 (18–87) (N = 3468)</td>
</tr>
<tr>
<td>Age at onset (yr)</td>
<td>22.8 ± 11.2 (0–74) (N = 1403)</td>
<td>27.6 ± 13.2 (1–78) (N = 3468)</td>
</tr>
<tr>
<td>MDD duration (yr)</td>
<td>22.1 ± 12.9 (0–68) (N = 1403)</td>
<td>18.7 ± 13.7 (0–71) (N = 3468)</td>
</tr>
<tr>
<td>Episode count</td>
<td>5.5 ± 8.2 (2–100) (N = 898)</td>
<td>4.0 ± 4.7 (2–50) (N = 2368)</td>
</tr>
<tr>
<td>Episode frequency (episodes/yr)</td>
<td>0.32 ± 0.36 (0.03–3.0) (N = 878)</td>
<td>0.29 ± 0.35 (0.03–3.0) (N = 2368)</td>
</tr>
</tbody>
</table>

Quantitative data are presented as mean±s.d. (range).

---

**Fig. 1.** Frequency distributions (histograms) of (a) age, (b) age at onset, (c) episode count and (d) episode frequency in genotyped cases (merged RADIANT and GSK Munich samples).
(depending on whether age was included as covariate in the model or not, respectively) and 0.15 and 0.33 for episodicity (depending on the method of calculation used, NB GLMM or LMM, respectively) (Table 4).

### SNP heritability of AAO and episode frequency

In the LMM for sqrtAAO \((N = 3468)\), we saved the residuals and then used them with the GREML procedure in GCTA software (Supplementary Table S5). The SNP heritability of sqrtAAO was calculated at 0.175 (S.E. = 0.104, \(p = 0.042\)).

In the NB GLMM of episodicity \((N = 2368)\), we saved episode frequency deviance residuals, rank-normalized them and then used them with the GREML procedure in GCTA software (Supplementary Table S6). The SNP heritability of episodicity was estimated at 0.092 (S.E. = 0.143, \(p = 0.260\)).

In the LMM of lnepisfreq, we saved lnepisfreq residuals, rank-normalized them and then used them with the GCTA software (Supplementary Table S7). The SNP heritability of episodicity was estimated at 0.129 (S.E. = 0.148, \(p = 0.192\)).

Power was 0.8 to detect a SNP heritability of 0.25 for AAO and 0.37 for episodicity.

### Discussion

Stratifying MDD cases by AAO and recurrence has extensively been used in MDD genetic research as early-onset and recurrent forms have been repeatedly associated with higher familial aggregation and heritability of MDD (Sullivan et al. 2000). However, there is paucity of evidence regarding the familiality and heritability of these MDD subphenotypes. By contrast, several other subphenotypes, such as symptom clusters or dimensions, illness chronicity, personality traits, subaffective temperament profile or suicidality, have been shown to be familial or heritable in MDD (Farmer et al. 2003; DiKeos et al. 2004; Korszun et al. 2004; Mondimore et al. 2006; McGirr et al. 2009; Aguiar Ferreira et al. 2013; Lai et al. 2013). Research into the genetic correlates of MDD subphenotypes might help elucidate the pathogenesis of MDD itself, given that it is phenotypically and genetically

---

### Table 3. Familiality of age at onset (AAO) and episodicity (two methods) in the DeNt affected full-siblings sample

<table>
<thead>
<tr>
<th>Dependent variable</th>
<th>Fixed effects</th>
<th>Random effects</th>
<th>Log-likelihood</th>
<th>Likelihood ratio test (one-tailed (\chi^2, df = 1))</th>
<th>(p) value</th>
<th>ICC</th>
</tr>
</thead>
<tbody>
<tr>
<td>AAO*</td>
<td>Sex</td>
<td>Center, family Center</td>
<td>-2108.30</td>
<td>29.32</td>
<td>&lt;0.001</td>
<td>0.278d</td>
</tr>
<tr>
<td></td>
<td>Sex, age</td>
<td>Center, family Center</td>
<td>-2122.96</td>
<td>16.11</td>
<td>&lt;0.001</td>
<td>0.229d</td>
</tr>
<tr>
<td>Episodicity (NB GLMM)b</td>
<td>Sex, age, center Family</td>
<td>-2040.70</td>
<td>80.47</td>
<td>&lt;0.001</td>
<td>0.074e</td>
<td></td>
</tr>
<tr>
<td>Episodicity (LMM)c</td>
<td>Sex, age</td>
<td>Center, family Center</td>
<td>-2048.75</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>-2310.95</td>
<td>7.56</td>
<td>0.003</td>
<td>0.167d</td>
</tr>
</tbody>
</table>

* Linear mixed model with sqrtAAO as dependent variable.
b Negative binomial generalized linear mixed model (NB GLMM) with episode count as dependent variable and (ln)MDD duration as offset variable.
c Linear mixed model (LMM) with ln(episode frequency) as dependent variable.
d Residual intraclass correlation coefficient (ICC) calculated in the ‘full’ model with all covariates.
e ICC calculated in a model without subject-level covariates (‘reduced’ model, i.e. without sex and age) (Carrasco, 2010).

---

### Table 4. Maximal heritability and SNP heritability estimates for age at onset (AAO) and episodicity in MDD

<table>
<thead>
<tr>
<th></th>
<th>Maximal heritability (s.e.)</th>
<th>SNP heritability (s.e.)</th>
</tr>
</thead>
<tbody>
<tr>
<td>(sqrt)AAO</td>
<td>0.56 (0.11)</td>
<td>0.17 (0.10)</td>
</tr>
<tr>
<td></td>
<td>0.46 (0.11)c</td>
<td>–</td>
</tr>
<tr>
<td>Episodicityd</td>
<td>0.15 (0.02)</td>
<td>0.09 (0.14)</td>
</tr>
<tr>
<td></td>
<td>0.33 (0.10)</td>
<td>0.13 (0.15)</td>
</tr>
</tbody>
</table>

d Maximal heritabilities, calculated as twice the ICC estimates from the DeNt affected full-siblings sample, provide an upper limit to narrow-sense heritability.

c Single nucleotide polymorphism (SNP) heritabilities in genotyped cases (merged RADIANT and GSK Munich samples) provide a lower limit to narrow-sense heritability.

e Two estimates are provided depending on whether age was included as covariate (lower line) in the model or not (upper line).

d Two estimates are provided depending on the method of calculation used (negative binomial generalized linear mixed model, upper line; linear mixed model, lower line; full details in text).
heterogeneous. Furthermore, assuming that specific subphenotypes are familial and heritable, one could further explore their pleiotropic cross-phenotype genetic correlations with other psychiatric disorders, medical co-morbidities, personality traits or environmental stressors (Lee et al. 2012; Solovieff et al. 2013).

This is the first study to systematically investigate the familiality of AAO and episodicity in MDD. The two subphenotypes were analyzed as continuous traits in mixed models, which allowed us to investigate their familial clustering as well as the strength of intranuclear environmental effects (Purcell, 2002; Purcell & Sham, 2002), also contribute. Furthermore, as more precise while the LMM method produces a count variable, we consider the NB GLMM method to be feasible for genotyped subjects after adding controls, few unaffected DeNt siblings were recruited and we, therefore, opted for the analysis of AAO as a quantitative trait in both datasets so that maximal heritability and SNP heritability estimates thence derived could be comparable.

Similarly, survival models for recurrent events (multiple-failure data) could be used to analyze episodicity (Baethe & Schlattmann, 2004). These models allow for the effects of prior episode number, therapeutic interventions, episode duration, episode-dependent covariates and unobserved heterogeneity (frailty) in recurrence-prone tendency on the risk of future recurrences (Kessing et al. 1999; Solomon et al. 2000) but could not be applied here as our data lacked information on timing and duration of each episode. Our NB model assumes that episodes are independent events while a semi-parametric survival model would withhold any assumptions about the distribution of episode count; the results of our analysis might, therefore, be subject to some bias.

Two genome-wide studies of the genetic architecture of AAO and episodicity in the RADIANT sample have been published. A GWAS of AAO, analyzed with three different methods, produced no genome-wide significant findings; a non-replicated genome-wide association with the TUSC3 gene in young males with an early AAO was recorded (Power et al. 2012). A preliminary estimate of 0.55 (s.e. = 0.27, p = 0.02) for the SNP heritability of (sqrt)AAO was also reported in this study. This earlier estimate, which is substantially higher than our current estimate, was based on AAO in UK cases only, and unadjusted for the effects of sex and cohort (study and center); in the present study, we adjusted sqrtAAO for these covariates, and extended the analysis to MDD cases ascertained from sites across Europe (including the UK) and one site in St Louis, USA. Similarly, a GWAS of episodicity in the RADIANT sample produced only non-replicated findings of suggestive significance; interestingly, polygenic profile analyses
based on the PGC MDD and bipolar studies showed that, in subjects with positive family history of MDD, episodicity was predicted by both MDD and bipolar polygenes (Ferentinos et al. 2014). These preliminary studies suggest that investigations in larger collaborative samples are certainly warranted.

Bipolar disorder, unlike MDD, shows evidence of the familiality and heritability of AAO and episodicity subphenotypes. Available studies are either based on extended families ascertained through bipolar probands and including relatives with major affective disorders or on clusters of bipolar siblings. AAO is familial, with reported ICC estimates of 0.1 (Schulze et al. 2006), 0.29 (O’Mahony et al. 2002) and 0.42 (Leboyer et al. 1998), while affected siblings of early-onset (AAO<21 years) probands were 4.5 times more likely than others to have an early onset (Lin et al. 2006). AAO was estimated to have a heritability of 0.52 in 27 extended families ascertained for bipolar disorder (Visscher et al. 2001). Episode frequency was significantly correlated among bipolar probands and their affected relatives with major affective disorders (ICC=0.56) (Fisfalen et al. 2005), refuting a previously reported much lower estimate of 0.15 which did not survive multiple testing correction (O’Mahony et al. 2002). Other subphenotypes have been shown to be familial in bipolar disorder, including psychotic symptoms, sleep disturbances, proportion of manic to depressive episodes, polarity at illness onset, suicidality, comorbidities (panic disorder, alcohol and substance abuse), and the quality of social relations (MacKinnon et al. 1997; Potash et al. 2001; O’Mahony et al. 2002; Dikeos et al. 2004; Kassem et al. 2006; Schulze et al. 2006; Lai et al. 2013).

Our study comes with some additional limitations. First, episode count was retrospectively self-reported during the SCAN interview without validation from external sources; it may be subject to recall bias and be influenced by the patient’s current mood state or personality characteristics (neuroticism, histrionic traits). Second, while maximal heritabilities of AAO and episodicity were derived from phenotypic correlations in a sample with familial MDD (DeNt siblings), SNP heritabilities were assessed in the merged RADIANT and GSK Munich sample where 54.4% of subjects had positive family history of MDD in first-degree relatives; low power did not allow us to recalculate SNP heritabilities for this specific subset. Third, ICC estimates were calculated in DeNt siblings suffering from recurrent MDD, and the SNP heritability of episodicity was assessed in 2368 genotyped cases with recurrent MDD; on the other hand, the SNP heritability of AAO was assessed in 3468 cases, of which 92% had recurrent MDD. Therefore, since heritabilities of AAO and episodicity might be different in familial v. non-familial MDD and in recurrent v. single episode forms, Table 4 should be interpreted with caution.

In conclusion, this study systematically investigated the familiality of AAO and episodicity in a sample of full siblings with recurrent MDD. Significant familiality of both was found; the strength of the familial effect was moderate for AAO and low for episodicity. An estimate of the upper limit to the narrow-sense heritability of the two subphenotypes was calculated from ICC values. AAO is under stronger additive genetic control than episodicity. We also estimated in unrelated MDD subjects the proportion of the variance of AAO explained by common SNPs (SNP heritability) with the GREML procedure in GCTA software. Analysis was underpowered for calculating SNP heritability of episodicity, confirming the need for larger samples. The statistical framework described here could be useful in future analyses. Assuming there is a substantial genetic basis for AAO and episodicity, one could further explore their pleiotropic genetic correlations with various other traits or conditions in order to unravel additional aspects in the pathogenesis, onset and course of MDD.

Supplementary material
For supplementary material accompanying this paper visit http://dx.doi.org/10.1017/S0033291715000215.

Acknowledgements
This study presents independent research part funded by a joint grant from the Medical Research Council, UK and GlaxoSmithKline (G0701420), and by financial support from the National Institute for Health Research (NIHR) Biomedical Research Centre for Mental Health at the South London and Maudsley NHS Foundation Trust and King’s College London. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health. This work was also supported by the German Federal Ministry of Education and Research within the context of the German National Genome Research Network (NGFN-2 and NGFN-plus). GlaxoSmithKline funded the collection of the DeNt cohort of depression cases, the genotyping of all RADIANT cases (with the MRC), and both the collection and genotyping of the GSK Munich cohort of depression cases. The GENDEP project was funded by the European Commission Framework 6 grant, EC Contract Ref.: LSHB-CT-2003-503428. Lundbeck provided nortriptyline and escitalopram for the GENDEP study. GlaxoSmithKline and the UK NIHR of the Department of Health contributed to the
funding of the sample collection at the Institute of Psychiatry, London. A.K. is supported through NIHR/BRC funding. R.U. was supported by a grant from the European Commission (Grant Agreement no. 115008). The sponsors had no role in the design and conduct of the study, in data collection, analysis, interpretation, writing of the report, or in the decision to submit the paper for publication. Dr. Aitchison holds an Alberta Centennial Addiction and Mental Health Research Chair, funded by the Government of Alberta. We are particularly grateful to Dr J. Carrasco for helpful comments on our statistical analysis.

Declaration of Interest

K. J. Aitchison, A. E. Farmer and P. McGuffin have received consultancy fees and honoraria for participating in expert panels for pharmaceutical companies including GlaxoSmithKline. M. Ising has received consultancy honoraria from MSD Merck. E. B. Binder has received grant support from PharmaNeuroboost. N. Henigsberg has participated in clinical trials sponsored by GlaxoSmithKline and Lundbeck. C. M. Lewis has received consultancy honoraria from Eli Lilly. There are no patents, products in development or marketed products to declare. All other authors declare no conflicts of interest.

References


https://doi.org/10.1017/S0033291715000215 Published online by Cambridge University Press


Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, Muller J, Sklar P, de Bakker PI, Daly MJ, Sham PC (2007). PLINK: a tool set for whole-genome association and population-based linkage analyses. *American Journal of Human Genetics* 81, 559–575.


Schulze TG, Hedeker D, Zandi P, Rietschel M, McMahon FJ (2006). What is familial about familial bipolar disorder? Resemblance among relatives across a broad spectrum of
phenotypic characteristics. Archives of General Psychiatry 63, 1368–1376.


StataCorp (2013). Stata Statistical Software: Release 13. StataCorp LP: College Station, TX.


